טוען...
Bridging Tumor Genomics to Patient Outcomes through an Integrated Patient-Derived Xenograft (PDX) Platform
New approaches to optimizing cancer drug development in both the laboratory and the clinic will be required to fully achieve the goal of individualized, precision cancer therapy. Improved preclinical models that more closely reflect the now recognized genomic complexity of human cancers are needed....
שמור ב:
| הוצא לאור ב: | Clin Lung Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4586173/ https://ncbi.nlm.nih.gov/pubmed/25838158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.03.001 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|